We advised the representatives of the several underwriters on the IPO

Davis Polk advised the representatives of the several underwriters in connection with AgomAb Therapeutics NV’s $200 million initial public offering of 12,500,000 American depositary shares, representing 12,500,000 common shares. The underwriters have a 30-day option to purchase up to an additional 1,875,000 ADSs from AgomAb at the initial public offering price. The ADSs are listed on the Nasdaq Global Select Market under the symbol “AGMB.”

AgomAb is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities, in order to overcome the limitations of prior therapeutic approaches. AgomAb’s mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.

The Davis Polk capital markets team included partners Marcel Fausten and Yasin Keshvargar and associate Kanger Jin. Partner David R. Bauer and associates Gabrielle Mazero and Bari Britvan provided intellectual property advice. Counsel Alon Gurfinkel and associates Kelli A. Rivers and Valentin Van de Walle provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post